Merrick I. Ross

3 ta ish

The University of Texas MD Anderson Cancer Center

1. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

   Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio +26

   Maqola20153 iqtibos

   ABIABI:AkademIndex/2026.other.047644

2. A randomized phase III trial of biochemotherapy versus interferon-α-2b for adjuvant therapy in patients at high risk for melanoma recurrence

   Kevin B. Kim, Sewa S. Legha, René González +18

   Maqola20092 iqtibos

   ABIABI:AkademIndex/2026.other.106252

3. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

   Christine N. Spencer, Jennifer L. McQuade, Vancheswaran Gopalakrishnan +86

   Maqola20212 iqtibos

   ABIABI:AkademIndex/2026.other.468922